Selecta Biosciences (NASDAQ:SELB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The brokerage presently has a $6.25 price target on the stock. Zacks Investment Research‘s price target indicates a potential upside of 5.75% from the stock’s current price.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
Several other equities analysts also recently commented on the company. BidaskClub downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Friday, October 5th. Stifel Nicolaus reiterated a “buy” rating on shares of Selecta Biosciences in a research report on Tuesday, October 23rd. Janney Montgomery Scott reiterated a “buy” rating on shares of Selecta Biosciences in a research report on Tuesday, October 23rd. Finally, Mizuho reiterated a “buy” rating and issued a $30.00 target price on shares of Selecta Biosciences in a research report on Wednesday, October 17th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $23.21.
Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Thursday, November 8th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.08. On average, analysts anticipate that Selecta Biosciences will post -3.07 EPS for the current year.
A number of institutional investors have recently bought and sold shares of SELB. Renaissance Technologies LLC bought a new position in Selecta Biosciences in the third quarter valued at about $196,000. Rhumbline Advisers raised its position in shares of Selecta Biosciences by 43.7% during the second quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock worth $222,000 after acquiring an additional 5,103 shares during the last quarter. MetLife Investment Advisors LLC bought a new position in shares of Selecta Biosciences during the third quarter worth about $225,000. Virtu Financial LLC bought a new position in shares of Selecta Biosciences during the third quarter worth about $363,000. Finally, Schwab Charles Investment Management Inc. raised its position in shares of Selecta Biosciences by 37.0% during the second quarter. Schwab Charles Investment Management Inc. now owns 33,700 shares of the company’s stock worth $447,000 after acquiring an additional 9,100 shares during the last quarter. Hedge funds and other institutional investors own 48.63% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Further Reading: Reverse Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.